Flu, cancer, HIV: after Covid success, what next for mRNA vaccines?

The technology was viewed with scepticism before the pandemic but there is now growing confidence about its use

It is one of the most remarkable success stories of the pandemic: the unproven technology that delivered the Moderna and Pfizer/BioNTech vaccines in record time, helping to turn the tide on Covid-19. The vaccines are based on mRNA, the molecule that instructs our cells to make specific proteins. By injecting synthetic mRNA, our cells are turned into on-demand vaccine factories, pumping out any protein we want our immune system to learn to recognise and destroy.

Pre-pandemic, the technology was viewed with scepticism - a clever concept, but not guaranteed to deliver. Now there is growing confidence that mRNA vaccines could have far-reaching applications in tackling diseases from flu to malaria.